Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
Caroline Atyeo, Stephanie Fischinger, Tomer Zohar, et al.
Immunity (2020) Vol. 53, Iss. 3, pp. 524-532.e4
Open Access | Times Cited: 379

Showing 1-25 of 379 citing articles:

Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1746
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 622-625
Open Access | Times Cited: 1232
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 971
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
Anthony T. Tan, Martin Linster, Chee Wah Tan, et al.
Cell Reports (2021) Vol. 34, Iss. 6, pp. 108728-108728
Open Access | Times Cited: 690
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer, et al.
Nature Medicine (2020) Vol. 27, Iss. 2, pp. 270-278
Open Access | Times Cited: 563
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19
Benjamin J. Meckiff, Ciro Ramírez-Suástegui, Vicente Fajardo, et al.
Cell (2020) Vol. 183, Iss. 5, pp. 1340-1353.e16
Open Access | Times Cited: 533
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann
Nature reviews. Immunology (2021) Vol. 21, Iss. 8, pp. 475-484
Open Access | Times Cited: 529
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
Katharina Röltgen, Abigail E. Powell, Oliver F. Wirz, et al.
Science Immunology (2020) Vol. 5, Iss. 54
Open Access | Times Cited: 468
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, et al.
Science Translational Medicine (2020) Vol. 13, Iss. 577
Open Access | Times Cited: 461
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2316-2331.e15
Open Access | Times Cited: 382
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
Tyler J. Ripperger, Jennifer L. Uhrlaub, Makiko Watanabe, et al.
Immunity (2020) Vol. 53, Iss. 5, pp. 925-933.e4
Open Access | Times Cited: 340
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
Nina Le Bert, Hannah Clapham, Anthony T. Tan, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 5
Open Access | Times Cited: 319
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold, et al.
Nature Medicine (2020) Vol. 27, Iss. 2, pp. 279-288
Open Access | Times Cited: 312
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Tomer Zohar, Carolin Loos, Stephanie Fischinger, et al.
Cell (2020) Vol. 183, Iss. 6, pp. 1508-1519.e12
Open Access | Times Cited: 309
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 282
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Carolina Lucas, Jon Klein, Maria E. Sundaram, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1178-1186
Open Access | Times Cited: 242
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Floriane Gallais, Pierre Gantner, Timothée Bruel, et al.
EBioMedicine (2021) Vol. 71, pp. 103561-103561
Open Access | Times Cited: 212
COVID-19 Antibody Tests and Their Limitations
Guoqiang Liu, James F. Rusling
ACS Sensors (2021) Vol. 6, Iss. 3, pp. 593-612
Closed Access | Times Cited: 198
Compromised SARS-CoV-2-specific placental antibody transfer
Caroline Atyeo, Krista M. Pullen, Evan A. Bordt, et al.
Cell (2020) Vol. 184, Iss. 3, pp. 628-642.e10
Open Access | Times Cited: 196
Overview of SARS-CoV-2 infection in adults living with HIV
Juan Ambrosioni, José Luís Blanco, Juliana Reyes‐Urueña, et al.
The Lancet HIV (2021) Vol. 8, Iss. 5, pp. e294-e305
Open Access | Times Cited: 175
Humoral signatures of protective and pathological SARS-CoV-2 infection in children
Yannic C. Bartsch, Chuangqi Wang, Tomer Zohar, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 454-462
Open Access | Times Cited: 163
Systems serology detects functionally distinct coronavirus antibody features in children and elderly
Kevin J. Selva, Carolien E. van de Sandt, Melissa M. Lemke, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 156
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
Ruklanthi de Alwis, Esther S. Gan, Shiwei Chen, et al.
Molecular Therapy (2021) Vol. 29, Iss. 6, pp. 1970-1983
Open Access | Times Cited: 149
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
Respirology (2021) Vol. 27, Iss. 4, pp. 301-310
Open Access | Times Cited: 149
Page 1 - Next Page

Scroll to top